Recruiting

Ivermectin

Sponsor:

Patrick Robinson

Code:

NCT05045937

Conditions

Covid19

COVID-19 Pneumonia

COVID-19 Respiratory Infection

COVID-19 Acute Bronchitis

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Accepted

Interventions

Ivermectin

Study Details

Brief summary:

Ivermectin is currently being utilized by a number of physicians in the local area. My objective will be to enroll these patients at the time of their evaluation for COVID-19 infection and to follow their progress through their recovery.

Conditions

Covid19

COVID-19 Pneumonia

COVID-19 Respiratory Infection

COVID-19 Acute Bronchitis

Study ID

NCT05045937

Start date

May 1, 2022

Status verified date

Apr, 2022

Completion date

May 1, 2024

Anticipated

Primary completion date

May 1, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Between the ages of 12-110 years old
  • Has a recently completed COVID test
  • Symptomatic and seeking treatment
  • Willingness to participate and have follow-up
  • Able and willing to take medications and treatment suggestions from the physician

Exclusion Criteria: Lack of symptoms, uncertain of COVID-19 status, outside of age limits for treatment

  • No recent COVID test results
  • Asymptomatic, even if COVID positive
  • Outside of acceptable age range
  • Meets criteria for hospital admission
  • Unwilling to participate in trial study or have follow-up

Study Design

Enrollment

1000 participants

Anticipated

Interventions and Outcome Measures

Arms

COVID-19 patients treated with Ivermectin

This group of patients will be those who requested to be treated with Ivermectin and whom have been prescribed such by different physicians. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.

COVID-19 patients declining Ivermectin and wanting traditional treatment

This group of patients will be those who do not request to be treated with Ivermerctin and who want to be treated with a more traditional, minimalist approach. This group may or may not include those treated with Monoclonal Antibodies or Remdesivir.

Interventions

Ivermectin

Ivermectin treatment of outpatients dosing at 0.4mg/kg until recovered along with supplemental treatment using a multi-modal approach.

Primary outcome measure

  • Complete recovery from COVID-19 with resolution of symptoms [ Time Frame: 4-6 weeks per individual ]
  • Admission to a hospital for further advanced treatment [ Time Frame: 4-6 weeks per individual ]

Central Contacts and Locations

Central contacts

Patrick R Robinson, MD

3862377150mustang6374@yahoo.com

Dana M Robinson, RN

8132156247dmvkar143@gmail.com

Locations

Patrick Robinson MD LLC

Recruiting

San Antonio, Florida, United States, 33576

Contacts

Patrick R Robinson, MD

386-237-7150mustang6374@yahoo.com

Dana M Robinson, RN

8132156247dmvkar143@gmail.com

More Information

Sponsor

Patrick Robinson

Last update posted

Apr 27, 2022

Last verified

Apr, 2022

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Patrick Robinson on 2022-04-27.